CatalymOncology Immunotherapy company
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients. It focuses on targeting growth differentiation factor 15 (GDF-15) to overcome cancer therapy resistance and improve treatment options.
- Category
- Oncology Immunotherapy
- Stage
- Series D
- Employees
- 61
- HQ
- Munich, Germany
- Founded
- 2016
- Funding
- $261M
